Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ptc Therapeutics (PTCT)

57   -0.32 (-0.56%) 03-03 16:40
Open: 57.42 Pre. Close: 57.32
High: 58.015 Low: 56.44
Volume: 390,520 Market Cap: 4,008M
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 58.819 - 59.129 59.129 - 59.392
Low: 56.359 - 56.709 56.709 - 57.006
Close: 56.749 - 57.339 57.339 - 57.842

Technical analysis

as of: 2021-03-03 4:08:22 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 71.74     One year: 77.10
Support: Support1: 54.00    Support2: 44.93
Resistance: Resistance1: 61.42    Resistance2: 66.01
Pivot: 58.83
Moving Average: MA(5): 56.97     MA(20): 59.88
MA(100): 60.53     MA(250): 53.28
MACD: MACD(12,26): -1.50     Signal(9): -1.35
Stochastic oscillator: %K(14,3): 30.16     %D(3): 26.80
RSI: RSI(14): 40.47
52-week: High: 70.82  Low: 30.79  Change(%): 3.0
Average Vol(K): 3-Month: 51644  10-Days: 53959

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
PTCT has closed above bottom band by 31.4%. Bollinger Bands are 0.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 03 Mar 2021
Analysts Offer Insights on Healthcare Companies: Antares Pharma (ATRS) and PTC Therapeutics (PTCT) - Smarter Analyst

Fri, 26 Feb 2021
When Will PTC Therapeutics, Inc. (NASDAQ:PTCT) Become Profitable? - Simply Wall St

Fri, 26 Feb 2021
PTC Therapeutics, Inc (PTCT) CEO Stuart Peltz on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha

Thu, 25 Feb 2021
PTC Therapeutics: 4Q Earnings Snapshot - San Francisco Chronicle

Thu, 25 Feb 2021
PTC Therapeutics EPS misses by $0.15, beats on revenue - Seeking Alpha

Thu, 25 Feb 2021
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 68
Shares Float (M) 63
% Held by Insiders 2.91
% Held by Institutions 106.46
Shares Short (K) 4,200
Shares Short P. Month (K) 4,910

Stock Financials

EPS -6.860
EPS Est This Year -2.350
EPS Est Next Year -1.970
Book Value (p.s.) 7.530
Profit Margin -123.20
Operating Margin -87.59
Return on Assets (ttm) -10.3
Return on Equity (ttm) -75.2
Qtrly Rev. Growth 65.8
Gross Profit (p.s.) 0.548
Sales Per Share 5.251
EBITDA (p.s.) -4.008
Qtrly Earnings Growth
Operating Cash Flow (M) -140
Levered Free Cash Flow (M) -103

Stock Valuations

PE Ratio -8.32
PEG Ratio
Price to Book value 7.58
Price to Sales 10.87
Price to Cash Flow -27.85

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.